U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17N2O5S.K
Molecular Weight 388.48
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENICILLIN V POTASSIUM

SMILES

[K+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC3=CC=CC=C3)C([O-])=O

InChI

InChIKey=HCTVWSOKIJULET-LQDWTQKMSA-M
InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H17N2O5S
Molecular Weight 349.382
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf

Penicillin V is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Penicillin V has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Penicillin V results from the inhibition of cell wall synthesis and is mediated through Penicillin V binding to penicillin binding proteins (PBPs). Penicillin V is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor. Used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms.

Originator

Curator's Comment: John C. Sheehan, a chemistry professor at Massachusetts Institute of Technology and a former chemist at Merck, synthesized phenoxymethylpenicillin, also known as penicillin V in 1957

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q8XJ01
Gene ID: 990276.0
Gene Symbol: pbpA
Target Organism: Clostridium perfringens (strain 13 / Type A)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15 mg/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
26.3 mg/L
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
35.5 mg/L
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.1 mg/L
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.01 mg × h/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
33.36 mg × h/L
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.94 mg × h/L
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.89 mg × h/L
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.78 h
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.91 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.05 h
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.52 h
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
unknown, oral
PENICILLIN V POTASSIUM serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Disc. AE: Stomach cramps, Nausea...
Other AEs: Diarrhea, Rash...
AEs leading to
discontinuation/dose reduction:
Stomach cramps (0.46%)
Nausea (0.46%)
Other AEs:
Diarrhea (0.8%)
Rash (1.2%)
Abdominal pain (0.8%)
Infection (1.7%)
Headache (1.2%)
Vomiting (2.5%)
Rhinitis (1.2%)
Gastroenteritis (0.4%)
Epistaxis (0.4%)
Ear pain (2.1%)
Cough increased (1.2%)
Nausea (0.8%)
Sources: Page: p.48
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.3A-25S
unhealthy, 16+
n = 117
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 16+
Sex: M+F
Population Size: 117
Sources: Page: p.3A-25S
Disc. AE: Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.7%)
Sources: Page: p.3A-25S
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Disc. AE: Nausea, Taste alteration...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 3, 0.88%)
Taste alteration (grade 3, 0.88%)
Sources: Page: p.341
800 mg 4 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 4 times / day
Route: oral
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 30.0 (6–73)
n = 212
Health Status: unhealthy
Condition: Pharyngotonsillitis caused by group A streptococci
Age Group: 30.0 (6–73)
Sex: M+F
Population Size: 212
Sources:
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 31.0 (3–67)
n = 210
Health Status: unhealthy
Condition: Pharyngotonsillitis caused by group A streptococci
Age Group: 31.0 (3–67)
Sex: M+F
Population Size: 210
Sources:
3 g multiple, oral
Recommended
Dose: 3 g
Route: oral
Route: multiple
Dose: 3 g
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Prophylaxis against bacterial endocarditis
Sources: Page: p.2
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Disc. AE: Rash, Vomiting...
AEs leading to
discontinuation/dose reduction:
Rash (0.57%)
Vomiting (0.57%)
Sources: Page: p.70/306
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Disc. AE: Hypersensitivity reaction, Diarrhea, Clostridium difficile...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (serious|grade 5)
Diarrhea, Clostridium difficile (mild|grade 5)
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Epistaxis 0.4%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Gastroenteritis 0.4%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Nausea 0.46%
Disc. AE
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Stomach cramps 0.46%
Disc. AE
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Abdominal pain 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Diarrhea 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Nausea 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Cough increased 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Headache 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Rash 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Rhinitis 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Infection 1.7%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Ear pain 2.1%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Vomiting 2.5%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Abdominal pain 1.7%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.3A-25S
unhealthy, 16+
n = 117
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 16+
Sex: M+F
Population Size: 117
Sources: Page: p.3A-25S
Nausea grade 3, 0.88%
Disc. AE
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Taste alteration grade 3, 0.88%
Disc. AE
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Rash 0.57%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Vomiting 0.57%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Diarrhea, Clostridium difficile mild|grade 5
Disc. AE
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Hypersensitivity reaction serious|grade 5
Disc. AE
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Assessment of the "E' book as a tool for drug monitoring.
1981 Mar
A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis.
2001 Dec
Biphasic illness pattern due to early relapse in Japanese-B virus encephalitis.
2001 Jan 15
Paediatric antibiotic prescribing by general dental practitioners in England.
2001 Jul
Determination of benzylpenicillin, oxacillin, cloxacillin, and dicloxacillin in cows' milk by ion-pair high-performance liquid chromatography after precolumn derivatization.
2001 Sep
Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects.
2001 Sep-Oct
Antibiotic prescribing in outpatients: a 1-week diagnosis-prescribing study in 5 counties in Sweden.
2002
Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero.
2002 Apr
Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin.
2002 Jul 31
Liquid chromatographic determination of ampicillin residues in porcine muscle tissue by a multipenicillin analytical method: European Collaborative Study.
2002 Jul-Aug
Substrate specificity of penicillin acylase from Streptomyces lavendulae.
2002 Mar 1
Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin.
2003
Telithromycin: new preparation. A needless addition to the other macrolides.
2003 Feb
Data from electronic patient records are suitable for surveillance of antibiotic prescriptions for respiratory tract infections in primary health care.
2004
Acute sinusitis: guide to selection of antibacterial therapy.
2004
Antibiotics for acute group A streptococcal pharyngitis.
2004 Dec
[Prevention and infection in adults patients with hyposplenism].
2004 Nov
Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.
2005
Antigen specific quantification of sulfidoleukotrienes in patients allergic to Betalactam antibiotics.
2005
Community prescribing and resistant Streptococcus pneumoniae.
2005 Jun
Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers.
2007 Dec
Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin.
2007 Jul
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.
2007 Jun
Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients.
2007 Mar
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.
2008 Aug
Effects of treatment with antimicrobial agents on the human colonic microflora.
2008 Dec
[Summary of the practice guideline 'Sore throat' (second revision) from the Dutch College of General Practitioners].
2008 Feb 23
Challenges of cellulitis in a lymphedematous extremity: a case report.
2009 Dec 22
Acute tonsillopharyngitis in a family practice in Mostar, Bosnia and Herzegovina.
2009 Mar
Synthesis of novel hapten and production of generic monoclonal antibody for immunoassay of penicillins residues in milk.
2013
Patents

Sample Use Guides

Usual Adult Dose for Bacterial Infection Mild to moderate infections: 125 to 500 mg orally every 6 to 8 hours
Route of Administration: Oral
Penicillin V inhibited Staphylococcus aureus in human THP-1 macrophages (intracellular) with MIC90 of 0.015 mg/L
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:03:29 GMT 2023
Record UNII
146T0TU1JB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENICILLIN V POTASSIUM
GREEN BOOK   HSDB   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
PENICILLIN V POTASSIUM [HSDB]
Common Name English
PENICILLIN PHENOXYMETHYL POTASSIUM
Common Name English
Monopotassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
Systematic Name English
ANTIBIOCIN
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM [EP MONOGRAPH]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENOXYACETYL)AMINO)-, MONOPOTASSIUM SALT, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-
Common Name English
PENICILLIN V POTASSIUM [USAN]
Common Name English
PRIMCILLIN
Common Name English
PENICILLIN POTASSIUM PHENOXYMETHYL
Common Name English
POTASSIUM PENICILLIN V
Common Name English
PENICILLIN VK
Brand Name English
PENAPAR-VK
Brand Name English
V-CILLIN K
Brand Name English
PENICILLIN V POTASSIUM [ORANGE BOOK]
Common Name English
PENICILLIN V POTASSIUM [USP-RS]
Common Name English
PENICILLIN V POTASSIUM [USP MONOGRAPH]
Common Name English
LEDERCILLIN VK
Brand Name English
NSC-757258
Code English
PHENOXYMETHYLPENICILLIN POTASSIUM [MART.]
Common Name English
Phenoxymethylpenicillin potassium [WHO-DD]
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM [WHO-IP]
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM
EP   JAN   MART.   WHO-DD   WHO-IP  
Common Name English
BEEPEN-VK
Brand Name English
PEN-VEE K
Brand Name English
UTICILLIN VK
Brand Name English
PENICILLIN V POTASSIUM [USP IMPURITY]
Common Name English
PFIZERPEN VK
Brand Name English
PENICILLIN V POTASSIUM SALT
MI  
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM [JAN]
Common Name English
PENICILLIN V POTASSIUM [GREEN BOOK]
Common Name English
VAMOSYN
Common Name English
PENICILLIN V POTASSIUM [VANDF]
Common Name English
VEETIDS
Brand Name English
BETAPEN-VK
Brand Name English
PHENOXYMETHYLPENICILLINUM KALICUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
Code System Code Type Description
CAS
132-98-9
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
MERCK INDEX
m8479
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY Merck Index
FDA UNII
146T0TU1JB
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
CHEBI
7967
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
RXCUI
203195
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY RxNorm
RS_ITEM_NUM
1504503
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
HSDB
6315
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
DRUG BANK
DBSALT000299
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PENICILLIN V POTASSIUM
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or with a faint characteristic odour. Solubility: Soluble in about 1.5 parts of water; practically insoluble in ether R. Category: Antibiotic. Storage: Phenoxymethylpenicillin potassium should be kept in a tightly closed container; protected from light. Additional information: Even in the absence of light, Phenoxymethylpenicillin potassium is gradually degraded on exposure to ahumid atmosphere, the decomposition being faster at higher temperatures. Definition: Phenoxymethylpenicillin potassium contains not less than 95.0% and not more than 102.0% of C16H17KN2O5S,calculated with reference to the dried substance.
EVMPD
SUB03766MIG
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
SMS_ID
100000090273
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
NSC
757258
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
NCI_THESAURUS
C730
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
DAILYMED
146T0TU1JB
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
ECHA (EC/EINECS)
205-086-5
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID7021102
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
PUBCHEM
23676814
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL615
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC